{"id":7291,"date":"2022-04-05T08:40:21","date_gmt":"2022-04-05T16:40:21","guid":{"rendered":"https:\/\/store.apotheraspecialtypharmacy.com\/?p=7291"},"modified":"2022-06-04T18:33:48","modified_gmt":"2022-06-05T02:33:48","slug":"opdualag-nivolumab-relatlimab-now-available-at-apothera","status":"publish","type":"post","link":"https:\/\/store.apotheraspecialtypharmacy.com\/?p=7291","title":{"rendered":"Opdualag (Nivolumab-Relatlimab), for the Treatment of Melanoma"},"content":{"rendered":"
Drug Info: ApoThera Drug Disease Clinical Support App<\/em><\/a><\/strong><\/div>\n
Melanoma<\/b><\/div>\n
Unresectable or Metastatic<\/i><\/b><\/div>\n
– 480mg\/160mg IV every 4 weeks<\/div>\n
– Continue until disease progression or unacceptable toxicity occurs<\/div>\n
<\/div>\n
\n
\n
Infusion-related Reactions<\/b><\/div>\n
Grade 1 or 2<\/i><\/b><\/div>\n
– Interrupt or slow infusion rate<\/div>\n
Grade 3 or 4<\/i><\/b><\/div>\n
– Permanently discontinue<\/div>\n
<\/div>\n
Females of Reproductive Potential<\/b><\/div>\n
– Use effective contraception during treatment with nivolumab and for at least 5 months following last dose of therapy<\/div>\n<\/div>\n
<\/div>\n
\n
\n
IV Administration<\/b><\/div>\n
– Administer the infusion over 30 minutes through an intravenous line containing a sterile, non-pyrogenic, low protein binding in-line polyethersulfone (PES), nylon, or polyvinylidene fluoride (PVDF) filter (pore size of 0.2 micrometer to 1.2 micrometer).<\/div>\n
– Flush the intravenous line at the end of the infusion.<\/div>\n
– Do not co-administer other drugs through the same IV line<\/div>\n<\/div>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Drug Info: ApoThera Drug Disease Clinical Support App Melanoma Unresectable or Metastatic – 480mg\/160mg IV every 4 weeks – Continue until disease progression or unacceptable toxicity occurs Infusion-related Reactions Grade…<\/p>\n","protected":false},"author":6,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"inline_featured_image":false,"footnotes":""},"categories":[16],"tags":[277,275,297,266,274,272,276,271,273],"class_list":["post-7291","post","type-post","status-publish","format-standard","hentry","category-blog","tag-bms","tag-cancer","tag-clinical-decision-support","tag-drug-information","tag-melanoma","tag-nivolumab","tag-opdivo","tag-opdualag","tag-relatlimab"],"jetpack_featured_media_url":"","jetpack-related-posts":[{"id":8022,"url":"https:\/\/store.apotheraspecialtypharmacy.com\/?p=8022","url_meta":{"origin":7291,"position":0},"title":"Risankizumab (SKYRIZI) Receives FDA Approval as the First and Only Specific Interleukin-23 (IL-23) to Treat Moderately to Severely Active Crohn’s Disease in Adults","date":"June 19, 2022","format":false,"excerpt":"Third approved indication for SKYRIZI (risankizumab-rzaa) is supported by safety and efficacy data from two induction and one maintenance clinical trials evaluating SKYRIZI in moderately to severely active Crohn's disease, ADVANCE, MOTIVATE and FORTIFY - As early as week 4 in the induction studies, clinical response and clinical remission were\u2026","rel":"","context":"In "Blog"","img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":7374,"url":"https:\/\/store.apotheraspecialtypharmacy.com\/?p=7374","url_meta":{"origin":7291,"position":1},"title":"FDA Pulls Authorization for GSK-Vir’s COVID Therapy, Sotrovimab, as BA.2 Cases Rise","date":"April 6, 2022","format":false,"excerpt":"The U.S. health regulator said on Tuesday GlaxoSmithKline (GSK.L) and Vir Biotechnology's (VIR.O) antibody therapy was no longer authorized as a COVID-19 treatment, with data suggesting it was unlikely to be effective against the dominant Omicron sub-variant in the country. Drug Information for COVID-19 Monoclonal Antibody (Bebtelovimab) and COVID-19 Polyclonal\u2026","rel":"","context":"In "Blog"","img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":7301,"url":"https:\/\/store.apotheraspecialtypharmacy.com\/?p=7301","url_meta":{"origin":7291,"position":2},"title":"Tezspire (Tezepelumab), Monoclonal Antibody for the Treatment of Severe Asthma","date":"April 5, 2022","format":false,"excerpt":"Drug Info: ApoThera Drug Disease Clinical Support App Severe Asthma - 210 mg SC every 4 weeks - Add-on maintenance treatment of severe asthma Missed Dose - Administer dose as soon as possible - Thereafter, resume dosing on the usual day of administration - If the next dose is already\u2026","rel":"","context":"In "Blog"","img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":7530,"url":"https:\/\/store.apotheraspecialtypharmacy.com\/?p=7530","url_meta":{"origin":7291,"position":3},"title":"Drug Information for COVID-19 Monoclonal Antibodies (Bebtelovimab) and Evusheld (Tixagevimab-Cilgavimab)","date":"April 8, 2022","format":"image","excerpt":"Drug Info: ApoThera Drug Disease Clinical Support App Drug Info: ApoThera Drug Disease Clinical Support App Drug Information for COVID-19 Monoclonal Antibodies (Bebtelovimab) and COVID-19 Polyclonal Antibody Evusheld (Tixagevimab-Cilgavimab) Available on ApoThera Clinical Decision Support Mobile \u00a0","rel":"","context":"In "Blog"","img":{"alt_text":"","src":"https:\/\/i0.wp.com\/store.apotheraspecialtypharmacy.com\/wp-content\/uploads\/2022\/04\/COVID.19.Viral_.Replication.and_.Symptom.Onset_.jpg?resize=350%2C200&ssl=1","width":350,"height":200},"classes":[]},{"id":7537,"url":"https:\/\/store.apotheraspecialtypharmacy.com\/?p=7537","url_meta":{"origin":7291,"position":4},"title":"Drug Info for Lagevrio (Molnupiravir), Oral Medication for the Treatment of Mild-to-Moderate COVID-19, Available on ApoThera Clinical Decision Support Mobile Application","date":"April 9, 2022","format":false,"excerpt":"Drug Information for Oral Medications for the Treatment of Mild-to-Moderate COVID-19, Paxlovid (Nirmatrelvir-Ritonavir) and Molnupiravir (Lagevrio), Available on ApoThera Clinical Decision Support Mobile Application Drug Info: ApoThera Drug Disease Clinical Support App Molnupiravir (Lagevrio) - 800 mg (four 200-mg capsules) by mouth every 12 hours x 5 days - Treatment\u2026","rel":"","context":"In "Blog"","img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":7212,"url":"https:\/\/store.apotheraspecialtypharmacy.com\/?p=7212","url_meta":{"origin":7291,"position":5},"title":"Rinvoq (upadacitinib) New Indications: Treatment of Moderate-to-Severe Ulcerative Colitis (UC)","date":"April 4, 2022","format":false,"excerpt":"Drug Info: ApoThera Drug Disease Clinical Support App Rinvoq (upadacitinib) receives FDA approval for the treatment of adults with moderately to severely active Ulcerative Colitis (UC) Induction Dose - 45 mg by mouth daily x 8 weeks Maintenance Dose - 15 mg by mouth daily - Use lowest effective dosage\u2026","rel":"","context":"In "Blog"","img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]}],"_links":{"self":[{"href":"https:\/\/store.apotheraspecialtypharmacy.com\/index.php?rest_route=\/wp\/v2\/posts\/7291","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/store.apotheraspecialtypharmacy.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/store.apotheraspecialtypharmacy.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/store.apotheraspecialtypharmacy.com\/index.php?rest_route=\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/store.apotheraspecialtypharmacy.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=7291"}],"version-history":[{"count":5,"href":"https:\/\/store.apotheraspecialtypharmacy.com\/index.php?rest_route=\/wp\/v2\/posts\/7291\/revisions"}],"predecessor-version":[{"id":7997,"href":"https:\/\/store.apotheraspecialtypharmacy.com\/index.php?rest_route=\/wp\/v2\/posts\/7291\/revisions\/7997"}],"wp:attachment":[{"href":"https:\/\/store.apotheraspecialtypharmacy.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=7291"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/store.apotheraspecialtypharmacy.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=7291"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/store.apotheraspecialtypharmacy.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=7291"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}